

# Pegfilgrastim Biosimilars Market Growth Analysis With Investment Opportunities For 2024-2033

*The Business Research Company's Pegfilgrastim Biosimilars Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033*

LONDON, GREATER LONDON, UK, July 29, 2024 /EINPresswire.com/ -- The pegfilgrastim biosimilars market has experienced robust growth in recent years, expanding from \$1.59 billion in

2023 to \$1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.



The Business  
Research Company

Pegfilgrastim Biosimilars Global Market Report 2024 :  
Market Size, Trends, And Global Forecast 2024-2033



You Can Now Pre Order  
Your Report To Get A Swift  
Deliver With All Your Needs  
-The Business Research  
Company”

*The Business Research  
Company*

## [Strong Future Growth Anticipated](#)

The pegfilgrastim biosimilars market is projected to continue its strong growth, reaching \$2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives.

Explore Comprehensive Insights Into The Global Pegfilgrastim Biosimilars Market With A Detailed Sample Report:

[https://www.thebusinessresearchcompany.com/sample\\_request?id=4015&type=smp](https://www.thebusinessresearchcompany.com/sample_request?id=4015&type=smp)

## Growth Driver Of The Pegfilgrastim Biosimilars Market

The increased incidence of cancer is expected to propel the pegfilgrastim biosimilars market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Pegfilgrastim biosimilars are used to reduce the risk of infection in

cancer patients undergoing chemotherapy by stimulating white blood cell production.

Order Your Report Now For Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report>

### Major Players And Market Trends

Key players in the pegfilgrastim biosimilars market include Coherus BioSciences, Sandoz, Biocon/Mylan, Intas Biopharmaceuticals Ltd., Mundipharma GmbH, Dr. Reddy's Laboratories, Pfizer Inc.

Major companies operating in the pegfilgrastim biosimilars market are launching high-quality pegfilgrastim biosimilars such as the Stimufend to provide better alternatives. Stimufend is a therapeutic drug designed to assist cancer patients in addressing neutropenia.

### Segments:

- 1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
- 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

### Geographical Insights: North America Leading The Market

North America was the largest region in the pegfilgrastim biosimilars market in 2023. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

### Pegfilgrastim Biosimilars Market Definition

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

Pegfilgrastim Biosimilars Global Market Report 2024 from The Business Research Company covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Pegfilgrastim Biosimilars Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on [pegfilgrastim biosimilars market size](#), pegfilgrastim biosimilars market drivers and trends, pegfilgrastim biosimilars market major

players, pegfilgrastim biosimilars competitors' revenues, pegfilgrastim biosimilars market positioning, and pegfilgrastim biosimilars market growth across geographies. The pegfilgrastim biosimilars market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report>

Oncology Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report>

Trastuzumab Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report>

### [About The Business Research Company](#)

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

### Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

### Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/731204033>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.